Rapidly growing sales for its two cystic fibrosis drugs led to Vertex Pharmaceuticals (NASDAQ: VRTX) being a top stock last year, and management hopes the FDA's sooner-than-expected approval of ...

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December.

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

Shares of Vertex Pharmaceuticals (VRTX 1.41%) fell 23.4% in October, ... Liver damage is one of the most common reasons companies stop development of drugs for safety concerns.

By developing drugs that act on the peripheral nervous system, Vertex aims to avoid the safety, tolerability, and addictive problems of drugs that act on the CNS. Vertex’s most advanced pain ...

Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain ...

Vertex Pharmaceuticals Inc. ended a closely watched effort to develop a therapy for liver disease, a setback in the biotech’s quest to broaden its offerings beyond cystic fibrosis drugs. The ...

Vertex Pharmaceuticals reported positive results Tuesday for two Phase 3 trials testing the efficacy and safety of pain compound VX-548 compared to either placebo or opioid-based treatment. While both ...

Vertex Pharmaceuticals' experimental cystic-fibrosis treatment met all of its main goals in a late-stage study when tested in patients aged 12 years and older, the company said on Monday.

Vertex Pharmaceuticals said Wednesday that the first late-stage trial of a potentially groundbreaking cystic fibrosis drug will be shorter than expected, prompting one analyst to forecast a ...